Photocure ASA - Annual Report 2009
Published: 26 March 2010Financial Investment & Stock
The Board of Directors of Photocure ASA approved the company's final annual accounts for 2009 on 18 February 2010, prior to the company's announcement and presentation of its fourth quarter results on 19 February 2010.
Please find a link to Photocure's Annual Report for 2009 in English, including annual accounts, the Board of Directors report, the Auditors report and the company's policy for Corporate Governance.
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM)platform.
For more information about Photocure, visit our website at www.photocure.com.
Photocure®, the Photocure logo and Hexvix® are registered trademarks of Photocure ASA.
For further information, contact:
Attn. Christian Fekete (CFO)
Mobile +47 916 42 938
E-mail: cf@photocure.no
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)